Category: StockGuru

Great Basin Scientific to Exchange 2015 Senior Secured Notes for Preferred Stock

SALT LAKE CITY, Nov. 03, 2016 (GLOBE NEWSWIRE) — Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced that it has entered into an agreement with holders of its 2015 Senior Secured Covertible Notes to exchange all of its approximately $8.5 million in principal for 8,436 shares of new Series F Convertible Preferred stock. The Company will also receive a release on the restrictions of approximately $3.6 million of cash from the restricted cash accounts upon closing of the exchange agreement.

Under the exchange agreement, each preferred share has a stated value of $1,000, and will be convertible into common stock during the first year at the fixed conversion price equal to $0.02, subject to certain antidilution adjustments. Beginning on the 8-month anniversary of the issuance of the preferred stock, the preferred stock will convert into common stock at a variable price of 85% of either the three lowest daily weighted average prices of the Company’s common stock during the 20 consecutive trading days ending on the trading day immediately preceding the date of determination or the weighted average price of the Company’s common stock on the trading day immediately preceding the date of determination, whichever is lower.

The preferred shares will automatically convert into shares of common stock at the following two dates: (1) On November 3, 2016, 2,098 preferred shares shall convert into 104.9 million shares of common stock at the fixed conversion price (or, if required by beneficial ownership limitations, held in abeyance by the Company for subsequent issuance to the appliable holder) and (2) On November 3, 2018, the second anniversary of the issuance date, in full, at the fixed conversion price.

The preferred stock will vote on an as-converted basis (subject to a 9.99% voting cap per holder) with the holders of the Company’s common stock on all matters subject to a vote of Great Basin common stockholders.

The Series F Preferred Shares and the shares of common stock issuable upon conversion of the Series F Preferred Shares have not been and will not be registered under the Securities Act of 1933, as amended, and may not be offered and sold absent such registration or an exemption from such registration requirements and in compliance with all applicable state securities laws and regulations. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

For additional information concerning the details of the exchange and the terms of the certificate of designations with respect to the Series F Preferred Shares, please refer to the Form 8-K the Company will file with the Securities and Exchange Commission.

About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.

Forward-Looking Statements
This press release includes forward-looking statement regarding events, trends and business prospects, which may affect future operating results and financial position, including but not limited to statements regarding the future conversion of the Series F Preferred Stock, the Company’s business development plans or other similar statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.  These forward-looking statements speak only as of the date hereof, and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

CONTACT: Media Contact:
Nirav Suchak

Investor Relations Contact:
Betsy Hartman
Great Basin Scientific

Geron Announces Presentations at American Society of Hematology Annual Meeting

MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the imetelstat program have been accepted for presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California from December 3-6, 2016. The abstracts were published today on the ASH website at

Oral Presentation

One abstract containing non-clinical data on imetelstat was selected for oral presentation. These data extend previous preclinical work conducted in a patient-derived model of acute myeloid leukemia.

Title: The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML – a randomized trial in patient-derived xenografts (Abstract #578)
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Targeting Leukemia-Initiating Cells
Session Date: Monday, December 5, 2016
Presentation Time: 7:15 a.m. PT

Poster Presentations

Three abstracts related to imetelstat were selected for presentation as posters. One abstract investigates the potential impact of imetelstat on leukemia stem cells in a non-clinical model of chronic myeloid leukemia. The second abstract reports new data on telomere length dynamics from essential thrombocythemia patients providing further support that imetelstat treatment may suppress the neoplastic clones underlying the disease. The third abstract presents an analysis of treatment patterns and outcomes of patients with myelofibrosis from the United States medical claims databases that underscores the need for additional treatment options in that disease.

Title: Telomerase Inhibition with Imetelstat Eradicates β-catenin Activated Blast Crisis Chronic Myeloid Leukemia Stem Cells (Abstract #3065)
Session Name: 632. Chronic Myeloid Leukemia: Therapy: Poster II
Session Date: Sunday, December 4, 2016
Session Time: 6:00 p.m. – 8:00 p.m. PT

Title: Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia (Abstract #1938)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Poster I
Session Date: Saturday, December 3, 2016
Session Time: 5:30 p.m. – 7:30 p.m. PT

Title: Characterization of Disease, Treatment Patterns, and Outcomes of Patients with Myelofibrosis: Analysis of 2 United States Commercial Claims Databases (Abstract #4769)
Session Name: 904. Outcomes Research – Malignant Conditions: Poster III
Session Date: Monday, December 5, 2016
Session Time: 6:00 p.m. – 8:00 p.m. PT

In accordance with ASH policies, abstracts submitted to the ASH Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the ASH Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the ASH Annual Meeting.

About Imetelstat

Imetelstat (GRN163L; JNJ-63935937) is a potent and specific inhibitor of telomerase that is administered by intravenous infusion. This first-in-class compound, discovered by Geron, is a specially designed and modified short oligonucleotide, which targets and binds directly with high affinity to the active site of telomerase. Preliminary clinical data suggest imetelstat has disease-modifying activity by inhibiting malignant progenitor cell clones associated with hematologic malignancies in a relatively select manner. Most commonly reported adverse events in imetelstat clinical studies include fatigue, gastrointestinal symptoms and cytopenias. Patients in these studies also experienced elevated liver enzymes, which resolved to normal or baseline in the majority of patients followed after imetelstat treatment was withdrawn. Imetelstat has not been approved for marketing by any regulatory authority.

About the Collaboration with Janssen

On November 13, 2014, Geron entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses. Under the terms of the agreement, Geron received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. All regulatory, development, manufacturing and promotional activities related to imetelstat are being managed through a joint governance structure, with Janssen responsible for these activities.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit

Use of Forward-Looking Statements

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding: (i) imetelstat having activity in other hematologic myeloid malignancies, including acute myeloid leukemia or chronic myeloid leukemia; (ii) imetelstat treatment suppressing the neoplastic clones underlying the disease in hematologic myeloid malignancies; (iii) the safety and efficacy of imetelstat; (iv) the potential receipt by Geron of additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, and royalties from sales of imetelstat; and (v) other statements that are not historical facts, constitute forward-looking statements. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (i) whether imetelstat will succeed in IMbarkTM and IMergeTM and potential future clinical trials by overcoming all of the clinical safety and efficacy, technical, scientific, manufacturing and regulatory challenges; (ii) Geron’s dependence on Janssen for the development, regulatory approval, manufacture and commercialization of imetelstat, including the risks that if Janssen were to breach or terminate the collaboration agreement or otherwise fail to successfully develop and commercialize imetelstat and in a timely manner, or at all, Geron would not obtain the anticipated financial and other benefits of the collaboration agreement with Janssen and the clinical development or commercialization of imetelstat could be delayed or terminated; (iii) the fact that Geron may not receive any milestone, royalty or other payments from Janssen because Janssen may terminate the collaboration agreement for any reason; (iv) whether imetelstat is safe and efficacious, and whether any future efficacy or safety results may cause the benefit/risk profile of imetelstat to become unacceptable and (v) whether imetelstat can be applied to any or to multiple hematologic malignancies. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors,” including Geron’s quarterly report on Form 10-Q for the quarter ended June 30, 2016. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.


Anna Krassowska, Ph.D.
Investor and Media Relations

Data for Prothena’s NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting

DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) — Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its NEOD001 Phase 1/2 dose-escalation and expansion study will be highlighted in two oral presentations, and data highlighting quality of life measures in patients with AL amyloidosis will be featured in three posters at the 58th Annual American Society of Hematology (ASH) Meeting to be held December 3-6, 2016, in San Diego, CA.

Clinical results of the Phase 1/2 dose-escalation and expansion study as of a May 9, 2016 data analysis were presented at the International Symposium on Amyloidosis (ISA) in Uppsala, Sweden on July 5, 2016. The two upcoming oral presentations at ASH will highlight additional aspects of the study results, as outlined below.

(Abstract #644) NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study

  • Presenter:  Morie A. Gertz, MD, Professor of Medicine, Mayo Clinic
  • Session:  653. Myeloma: Therapy, Excluding Transplantation: Amyloidosis
  • Date and Time:  Monday, December 5, 7:15 AM PT
  • Location:  San Diego Convention Center, Hall AB

This presentation will contain updated patient case study data.

(Abstract #647) Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response

  • Presenter:  Michaela Liedtke, MD, Stanford Comprehensive Cancer Center
  • Session:  653. Myeloma: Therapy, Excluding Transplantation: Amyloidosis
  • Date and Time:  Monday, December 5, 8:00 AM PT
  • Location:  San Diego Convention Center, Hall AB

This presentation will contain data demonstrating that patients treated with monthly NEOD001 infusions had favorable organ response rates that were independent of time since prior plasma cell dyscrasia (PCD) treatment, depth of hematologic response, or predominant type of PCD treatment.

In addition, three posters that highlight quality of life measures in patients with AL amyloidosis will also be presented:

(Abstract #3596) Burden of AL Amyloidosis on Health-related Quality of Life in Clinic-based, Community-based, and Trial-based Studies

  • Presenter:  Spencer Guthrie, Head of Development Affairs, Prothena Biosciences Inc
  • Session:  904 – Outcomes Research – Malignant Conditions: Poster II
  • Date and Time:  Sunday, December 4, 6:00 – 8:00 PM, PT
  • Location:  San Diego Convention Center, Hall GH

(Abstract #3586) Changes in Health-related Quality of Life Corresponding to Hematologic Response to Treatment in AL Amyloidosis

  • Presenter:  Vaishali Sanchorawala, M.D., Assoc. Director, Amyloidosis Center, Boston University Medical Center
  • Session:  903 – Outcomes Research – Non-malignant Conditions: Poster II
  • Date and Time:  Sunday, December 4, 6:00 – 8:00 PM, PT
  • Location: San Diego Convention Center, Hall GH

(Abstract #4753) Treatment-related Symptoms and Impact on Health Related Quality of Life in AL Amyloidosis

  • Presenter:  Michelle K. White, PhD, Sr. Scientist and Sr. Director, Optum
  • Session:  903 – Outcomes Research – Non-malignant Conditions: Poster II
  • Date and Time:  Sunday, December 4, 6:00 – 8:00 PM, PT
  • Location:  San Diego Convention Center, Hall GH

About NEOD001

NEOD001 is a monoclonal antibody that specifically targets the circulating soluble amyloid and deposited insoluble amyloid that accumulates in both the AL and AA forms of amyloidosis. Patients with AL amyloidosis may be eligible to enroll in one of two clinical studies for NEOD001. The PRONTO study, a global, Phase 2b, double-blind, placebo-controlled, registration-directed study, will evaluate NEOD001 in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction, and will assess best response over 12 months of the cardiac functional biomarker NT-proBNP, defined by the consensus criteria of NT-proBNP change, in addition to other biomarker, quality of life and functional endpoints. The VITAL Amyloidosis Study, a global, Phase 3, double-blind, placebo-controlled, registrational study, is evaluating NEOD001 in newly-diagnosed, treatment-naïve patients with AL amyloidosis, and will assess a composite endpoint of all-cause mortality or cardiac hospitalizations in addition to biomarker, quality of life and functional endpoints. More information on the PRONTO study and The VITAL Amyloidosis Study is available at, by searching NCT #02632786 for PRONTO, and NCT #02312206 for VITAL or, by searching EudraCT #2015-004318-14 for PRONTO, and EudraCT #2014-003865-11 for VITAL.

About AL Amyloidosis

Systemic amyloidoses are a complex group of progressive diseases caused by tissue deposition of misfolded proteins that result in progressive organ damage. The most common type, AL amyloidosis or primary amyloidosis, involves a hematological disorder caused by plasma cells that produce misfolded AL protein resulting in deposits of abnormal AL protein (amyloid) in the tissues and organs of individuals with this disease. There are no approved treatments for AL amyloidosis that directly target potentially toxic forms of the AL protein. AL amyloidosis is a rare disorder and it is estimated that about 30,000 to 45,000 patients in the U.S. and Europe suffer from this disease. Both the causes and origins of AL amyloidosis remain poorly understood. For more information on AL amyloidosis, please visit the websites of the Amyloidosis Support Group and the Amyloidosis Foundation.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company’s website at

CONTACT: Contacts:

Investors: Tran Nguyen, CFO

Media: Ellen Rose, Head of Communications 

York Water Company Reports 3rd Quarter and Nine Months Earnings and Announces a Water Acquisition

YORK, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) — The York Water Company’s (NASDAQ:YORW) President, Jeffrey R. Hines, announced today the Company’s financial results for the third quarter and the first nine months of 2016.

President Hines reported that third quarter 2016 operating revenues of $12,601,000 increased $233,000 and net income of $3,571,000 increased $51,000 compared to the third quarter of 2015.  Earnings per share of $0.27 for the three-month period decreased $0.01 compared to the same period last year due to an increase in the number of shares outstanding.

President Hines also reported that operating revenues for the first nine months of 2016 of $35,699,000 increased $227,000, due to the addition of nearly 1,000 new customers and higher service revenues. Net income of $8,904,000 decreased by $69,000 compared to the first nine months of 2015 despite the increase in revenue primarily due to higher depreciation expense and higher income taxes due to reduced maintenance and repair tax deductions.  Other operating expenses were consistent or lower for the first nine months of 2016 compared to the same period in 2015.  Earnings per share for the nine-month period were $0.69 in 2016 and $0.70 in 2015.

During the first nine months of 2016, the Company invested $8.3 million in construction expenditures for further upgrades to water treatment facilities and information technology, as well as various replacements of infrastructure and other routine items.  In addition, the Company invested $29,000 in the acquisition of water facilities.  The Company estimates it will invest an additional $4 million in 2016, excluding acquisitions, for expansion and improvements to its pipes, service lines, water and wastewater treatment facilities, an additional untreated water pumping station and force main, and various replacements and upgrades to other infrastructure to ensure a safe, adequate, and reliable supply of drinking water and to maintain proper handling and disposal of wastewater for the Company’s growing customer base. 

  Period Ended September 30
  In 000’s (except per share)
  Quarter Nine Months
    2016     2015     2016     2015  
Operating Revenues $ 12,601   $ 12,368   $ 35,699   $ 35,472  
Net Income $   3,571   $   3,520   $    8,904   $    8,973  
Average Number of Common Shares Outstanding       12,868     12,835     12,847     12,844  
Basic Earnings Per Common Share $   0.27   $   0.28   $   0.69   $   0.70  
Dividends Declared Per Common Share $ 0.1555   $ 0.1495   $ 0.4665   $ 0.4485  

On August 8, 2016, the Company signed an agreement to purchase the water assets of Stockham’s Village Mobile Home Park in Adams County, Pennsylvania.  Completion of this acquisition is contingent upon receiving approval from all required regulatory authorities.  The Company expects to begin serving approximately 80 new customers through an interconnection with its current distribution system in the first quarter of 2017.

This news release may contain forward-looking statements regarding the Company’s operational and financial expectations. These statements are based on currently available information and are subject to risks, uncertainties, and other events which could cause the Company’s actual results to be materially different from the results described in this statement. The Company undertakes no duty to update any forward-looking statement.

CONTACT: Contact:
Jeffrey R. Hines, President
Kathleen M. Miller, Chief Financial Officer 

GCP Applied Technologies Building Materials Featured on This Old House®

CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) — GCP Applied Technologies (NYSE:GCP), formerly part of W.R. Grace, is pleased to announce that its flagship product, Ice & Water Shield® self-adhered roofing underlayment and latest residential building envelope innovation, Vycor® enV-S™ self-adhered weather resistive barrier, were used in the renovation of the This Old House® Arts & Crafts  project airing now on PBS (check local listings).

“We are proud to work with the This Old House crew on another unique home project,” said Sonya Santos, Director of Marketing for GCP’s Residential Building Materials business. “It is one of our greatest honors to have our Ice & Water Shield®, which has been trusted for nearly 40 years, used by such a highly trusted brand and team of respected home renovation experts.”

The new This Old House® episodes feature the renovation of an Arts & Crafts home in Arlington, Massachusetts. Original Grace Ice & Water Shield® was used on the roof of the Arlington home to protect it from extreme weather such as wind-driven rain and ice dams. The underlayment seals around the fasteners used to attach the shingles, which helps prevent water build up from leaking into the house. Ice & Water Shield® also sticks to the roof deck so that water may not travel under the underlayment and enter the house via a vulnerable roof deck joint. The episode that includes Ice & Water Shield® is titled “To Paint or Not to Paint,” number 1507/3607 and airs on PBS beginning November 10, 2016 (check local listings).

“The This Old House crew also selected our advanced weather barrier, Vycor® enV-S™, an advanced alternative to house wrap. This weather resistive barrier represents the latest in residential building science to create an air-tight, yet breathable home, and achieve the highest product performance available,” said Sonya Santos.

The well-respected Oak Ridge National Lab tested and evaluated the annual savings potential of Vycor® enV-S™ membrane compared to traditional house wrap. Vycor® enV-S™ weather resistive barrier boasts an air leakage rate 7 times lower than the leading house wrap brand. The Oak Ridge Lab also found that using this new and advanced membrane can provide significant energy savings for homeowners in all regions of the United States.

The new This Old House® Season 37 episodes air nationally on PBS. To find out exactly when an episode will air in your area, check your local listings here.  Episodes also stream digitally at

About GCP Applied Technologies Inc.

Through applied knowledge and service excellence, GCP Applied Technologies (NYSE:GCP) provides premier specialty construction chemicals and specialty building materials for many of the world’s most renowned structures, and packaging technologies for the best-known consumer brands, delivering results for all our customers. With customers in 110 countries, operations on six continents, and a team of approximately 2,850 employees, GCP Applied Technologies had 2015 net sales of US $1.4 billion. Formerly part of the W.R. Grace & Co. group, GCP Applied Technologies Inc. became a NYSE-listed company in February 2016, headquartered in Cambridge, Massachusetts, USA. More information is available at

CONTACT: Media Relations 
Paul Keeffe 
+1 617.498.4461 

Investor Relations 
Joe DeCristofaro 
+1 617.498.2616

RENT-A-CENTER INVESTOR REMINDER: Hagens Berman Reminds Investors in Rent-A-Center of Investigation Into Possible Securities Law Violations

SAN FRANCISCO, Nov. 03, 2016 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP reminds investors in Rent-A-Center of the firm’s investigation into potential misstatements that may violate the federal securities laws.

If you purchased or otherwise acquired securities of Rent-A-Center during 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

Rent-A-Center shares tumbled over 28% on heavy trading on October 11, 2016, the same day the Company disclosed it was continuing to experience issues with its new Point-of-Sale [POS] system that would have a larger than expected negative impact on Company sales.

The Company’s disclosures apparently represent a complete reversal from its prior statements made on July 28, 2016, in which RCII management noted that POS system issues were fixed and the “distraction” of implementing the POS system was alleviated.

It appears that RCII has still not fully remedied its POS system issues.  On October 26, 2016, Rent-A-Center disclosed “[c]ore U.S. revenue decreased by 16.3 percent” and “[c]ore U.S. same store sales decreased by 12.0 percent driven by the store information management system implementation and system outages[.]”

“Whenever a company’s management says significant business issues are fixed, reasonable investors are entitled to take those statements at face value without having to independently vet them,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Rent-A-Center should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

CONTACT: Contact:
Reed Kathrein, 510-725-3000

Key Financial Announces Local CEO Call to Action

WEST CHESTER, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) — Recently, Key Financial Inc. hosted their first ever “CEO for the Day”, where a local 12 year old was given the opportunity to shadow President and CEO Patti Brennan. The idea first came to Brennan after meeting Wyatt through the ‘Believe and Achieve’ program at the West Chester YMCA, where the two discussed how leaders lead, and the best ways to learn.

“We were thrilled to hear that Wyatt would be shadowing Patti as our CEO for the Day,” states Director of Communications Bernadette Hunter. “We wanted to make his experience at Key Financial as real and hands on as possible, so that he could leave with a real sense of what his future could hold.” Wyatt’s day was filled with various activities such as signing letters and delegating tasks to employees- he even had his own business card and parking spot! Patti and the team at Key Financial plan to turn the experience into an annual event, and urge other CEOs of companies in our community to host their own CEO for the Day.

“The experience was invaluable to everyone who participated in this event,” says president and CEO Patti Brennan. “It was wonderful to see the way everyone rallied together to make this day special. Our biggest hope is that this experience can create a ripple effect, inspiring other local community leaders to join in inspiring today’s youth.”


A graduate of Georgetown University, Patti is a Certified Financial Planner with almost 30 years of experience providing financial advice in West Chester, PA.  In addition to being President and CEO of Key Financial, Inc. she also serves on the National Advisory Board, is a Board Member of the YMCA of Greater Brandywine and Cuddle My Kids.  She formerly served on the Boards of the Chester County Economic Development Council, SEEDCO and Penn Medicine Chester County Hospital.

Securities offered through Royal Alliance Associates, Inc., member FINRA/SIPC. Insurance services offered through Patricia Brennan are independent of Royal Alliance Associates, Inc. Advisory services offered through Key Financial, Inc., a registered investment advisor not affiliated with Royal Alliance Associates, Inc.

Photos accompanying this announcement are available at

CONTACT: Contact:
Bernadette Hunter

Guggenheim Securities Hires Jonathan Schildkraut to Expand TMT Equity Research

NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) — Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Jonathan Schildkraut has joined the firm as a Senior Managing Director and Senior Analyst in Equity Research. Mr. Schildkraut is joining the Technology, Media, and Telecommunications (TMT) research team, specifically focusing on Communications Infrastructure and Telecom Services.

Mr. Schildkraut joins Guggenheim from Evercore ISI, where he was a Senior Managing Director. Prior to Evercore, he served as a Managing Director and Senior Analyst at Jefferies & Company. Before joining Jefferies, Mr. Schildkraut was an equity research analyst at SG Cowen Securities covering telecom and data center services. He has almost 20 years of experience covering and working in the telecommunications industry and began his career at Salomon Smith Barney. Mr. Schildkraut’s research has earned recognition by third parties such as Thomson Reuters, Forbes, and Institutional Investor magazine, where he was named a member of the “2016 All-America Research Team” in the Communications Infrastructure sector.  

“Jonathan is a valuable addition to the strategic expansion of our firm’s research efforts in tech, media, and telecom,” said Jerry Donini, Co-CEO of Guggenheim Securities. “Jonathan has a strong track record of engaging with clients and providing alpha-generating insight into a dynamic industry. His research coverage will be a strong complement to our existing TMT franchise in Media & Entertainment, Cable & Satellite, Enterprise IT & Software, and eTravel & Internet.”

Mr. Schildkraut received his JD and MBA from New York University and his BA from the University of Michigan. He is based in Guggenheim’s New York office.

About Guggenheim Partners 

Guggenheim Partners is a global investment and advisory firm with more than $250 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With 2,500 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting and following us on Twitter at

1Assets under management are as of 9.30.2016 and include consulting services for clients whose assets are valued at approximately $60bn.

CONTACT: Media Contact

Ellen Cunningham       
Guggenheim Partners

Foundation for a Drug-Free World Treats Lealman to the Truth About Drugs for Halloween

LEALMAN, Fla., Nov. 03, 2016 (GLOBE NEWSWIRE) — On Oct 31, 2016, volunteers from the Foundation for a Drug-Free World Florida participated in Halloween Trick or Treating by passing out candy and the Truth About Drugs booklets at the Police Athletic League center in Lealman, Florida.

The volunteers set up a booth at a Halloween party in the unincorporated City of Lealman, where they distributed candy to the eager Trick or Treaters and drug education booklets to their parents.

“Parents were very happy to receive our booklets. They provide the knowledge necessary for them to educate their kids,” said Joe Creek, Drug-Free World volunteer. “Some people took a handful to give to additional friends and family members.”

The Truth About Drugs is a program to educate youth and adults with factual information about drugs so they can make informed decisions. Through a worldwide network of volunteers, 50 million drug prevention booklets have been distributed and tens of thousands of drug awareness events have been held in some 180 countries.

The Foundation for a Drug-Free World is one of the many humanitarian programs that members of the Church of Scientology support to improve communities everywhere. The Church of Scientology Flag Service Organization opened the Foundation for a Drug-Free World’s facilities in downtown Clearwater last year in an effort to make a difference in the Tampa Bay area.

“We are very glad to have the opportunity to help prevent people from going down the road of drug abuse,” said Dylan Pires, Community Affairs Director for the Church of Scientology Flag Service Organization. “It is just like L. Ron Hubbard said, ‘The single most destructive element in our current culture is drugs.’”

About the Church of Scientology:

The Scientology religion was founded by humanitarian and philosopher, L. Ron Hubbard. The first Church of Scientology was formed in the United States in 1954 and has expanded to more than 11,000 churches, missions and affiliated groups, with millions of members in 165 nations. Scientologists are optimistic about life and believe there is hope for a saner world and better civilization, and actively do all they can to help achieve this. To learn more, visit

CONTACT: Dylan Pires
(727) 467-6860

Women’s Business Development Center Annual “Just Desserts” Event: a Celebration of the Sweet Success of Women Business Owners

PHILADELPHIA, Nov. 03, 2016 (GLOBE NEWSWIRE) — The Women’s Business Development Center (WBDC) annual fundraiser, “Just Desserts” – Celebrating the Sweet Success of Women Business Owners, was held Wednesday, November 2, 2016 at the Union League.

The night included a cocktail reception with networking, a business showcase, dinner buffet with desserts and the ever popular, Desserts-to-Go table. More than 250 attendees feasted on the delectable desserts contributed by women-owned restaurants, bakeries and caterers including Bourbon Blue, Bredenbeck’s Bakery, Metropolitan Bakery and Sweet Pea Catering.

Wendy Saltzman, 6abc Action News investigative reporter, was the Mistress of Ceremonies and introduced three women who shared their business venture stories:

  • Michelle Carfagno, CEO, The Greater Knead – a gluten- and allergen-free bagel company aimed at creating transparency in the food industry
  • Peggy DelFabbro, CEO, M. Davis & Sons, Inc. – a fifth-generation industrial construction company that builds, installs and maintains corporate plants and facilities for national and international companies
  • Sharon Leaks Morgan, President, S&B Organic Cleaning Solutions LLC – a commercial and residential cleaning company that uses organic products

“Wells Fargo is proud to again be the presenting sponsor of the Women’s Business Development Center’s Just Desserts event,” said Greg Redden, Wells Fargo’s Regional President for Greater Philadelphia and Delaware. “WBDC has had a measurable impact on our region, having served more than 30,000 women since its inception in 1995, improving the quality of their lives and contributing to the economic stability of our communities – one business at a time. Wells Fargo shares the same commitment to women business owners.

Each year, WBDC provides more than 3,500 women with inspiration, encouragement, empowerment, and the tools they need to be successful. The organization serves a wide range of women who represent various sectors of the economy. Many start micro enterprises that provide needed services in their local communities. Programs provide coaching, training, technical assistance, and woman business enterprise certification. WBDC also opens doors that provide connections to new markets and access to capital.

Funds raised from “Just Desserts” will help WBDC continue to offer tools and training to current and future women business owners to help turn their dreams of entrepreneurship into a reality.

About the Women’s Business Development Center
Formed in July 1995 with the assistance of a matching grant from the U.S. Small Business Administration’s Office of Women Business Ownership, the Women’s Business Development Center (WBDC) fosters the development and retention of successful businesses by delivering resources that enable individuals to start new businesses and grow existing ones. While the center is dedicated to the economic empowerment of women, the services are open to all individuals. For more information, visit its website –


Historic Fort Harrison features “Spooktacular” Old-Time Radio Show Dramatic Reading

CLEARWATER, Fla., Nov. 03, 2016 (GLOBE NEWSWIRE) — On Saturday October 29th, the Halloween-themed Old Time Radio Show reading of L. Ron Hubbard’s 1936 classic suspense tale “The Death Flyer” came to life in the Crystal Ballroom of the Church of Scientology Flag Service Organization’s Fort Harrison courtesy of the East Coast Golden Age Theater. In addition to providing unique entertainment, the performance also raised donations to support “Toys for Tots” for underprivileged children in the Tampa Bay area.

A photo accompanying this announcement is available at

The reading included sound effects, reminiscent of an old time radio show. The dramatic reading cast comprised Tampa Bay residents: Colin Taufer, Nick Koenig, Josh Greenburg, Somali Rose, narrator/producer Joanie Sigal and director Kathy Sweigart.

The director of a local travel club brought two dozen members of her group.  The director said, “This event exceeded all expectations. The readers made the plot come alive. It was a day we shall be talking about for some time to come.”

“The theater was founded in 2011 with the purpose of encouraging reading by doing dramatic presentations of fiction short stories written by Mr. Hubbard in the 30s and 40s,” said Joanie Sigal, the theater’s producer. “Since then we have performed for thousands of school children and adults.”

While most of their performances have been in Florida, the theater has also performed at Books-a-Million in Bangor Maine, Columbia University in New York and for the Boys & Girls Club in Harlingen, Texas.

For more information about upcoming community events, please contact Amber Skjelset, Manager of the Scientology Information Center, at 727-467-6966 or e-mail her at

The Church of Scientology
The Scientology religion was founded by humanitarian and philosopher, L. Ron Hubbard and incorporated in 1954. It has since expanded to more than 11,000 churches, missions and affiliated groups in 167 nations. The Fort Harrison located in downtown Clearwater was built in 1927 and has been owned by the Church of Scientology Flag Service Organization since 1975.  In March 2009 the Church completed a top-to-bottom restoration and has since hosted over 700 events for the community in the Fort Harrison’s auditorium and Crystal Ballroom. To learn more, visit

CONTACT: For more information
Contact: Amber Skjelset
(727) 467-6966

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to Ring The Nasdaq Stock Market Closing Bell


Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Michael G. Kauffman, M.D., Ph.D., Director, and Chief Executive Officer, will ring the Closing Bell. 

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

Friday, November 4, 2016 – 3:45 p.m. to 4:00 p.m. ET   

Karyopharm Contact:
Gina Nugent
(617) 460-3579

Nasdaq MarketSite:
Emily Pan
(646) 441-5120

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:

For photos from ceremonies and events, please visit our Instagram page:

For livestream of ceremonies and events, please visit our YouTube page:

For news tweets, please visit our Twitter page:

For exciting viral content and ceremony photos, please visit our Tumblr page:

A live stream of the Nasdaq Closing Bell will be available at: or

To obtain a hi-resolution photograph of the Market Close, please go to and click on the market close of your choice.

About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm’s SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company’s initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,700 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in acute myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others.  Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017.  In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 18,000 corporate clients. To learn more, visit: or


Albireo Completes Transaction with Biodel to Create Publicly Traded Company Focused on Orphan Pediatric Liver Diseases

— Albireo Pharma, Inc. to trade on The NASDAQ Capital Market under symbol “ALBO”

— Company to develop novel bile acid modulators to treat orphan pediatric liver diseases, other liver and gastrointestinal diseases —

BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) — Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators through its operating subsidiary, today announced the completion of the share exchange transaction between Biodel Inc. (NASDAQ:BIOD) (through November 3) and Albireo Limited and its shareholders and noteholders, effective as of November 3, 2016.  The combined organization will be called Albireo Pharma, Inc. and will commence trading on The NASDAQ Capital Market on November 4, 2016 under the symbol “ALBO.”

Completion of the share exchange, together with $10 million in new capital invested prior to the closing by existing Albireo Limited investors, provides approximately $30 million to enable Albireo to advance development of its pipeline, including its lead product candidate, A4250, in development for the treatment of progressive familial intrahepatic cholestasis (PFIC).  PFIC is a life-threatening orphan liver disease that affects young children.

“The completion of the share exchange is an exciting step in the evolution of Albireo as we enter the public markets with funding expected to be sufficient to progress A4250 into a planned pivotal trial in PFIC, which we anticipate starting next year,” said Ron Cooper, President and Chief Executive Officer of Albireo.  “We believe A4250 has the potential to become a much needed, nonsurgical treatment option for children suffering from PFIC or other rare cholestatic liver diseases.”

On November 3, 2016, prior to the closing of the share exchange, Biodel completed a one-for-thirty reverse stock split.  As a result of the reverse stock split, every 30 shares of Biodel common stock outstanding immediately prior to the share exchange was combined and reclassified into one share of Biodel common stock.  No fractional shares are being issued in connection with the reverse stock split.  Instead of fractional shares, cash will be issued based on the closing price of Biodel common stock on The NASDAQ Capital Market on November 2, 2016.

The holders of ordinary shares of Albireo Limited immediately prior to the share exchange received 0.06999 shares of Biodel common stock in exchange for each ordinary share.  This exchange ratio reflects the reverse stock split.  Following the reverse stock split and the share exchange, Albireo has approximately 6,294,725 shares outstanding.

The combined organization will operate under the leadership of Albireo’s officers, including: Ron Cooper, President and Chief Executive Officer; Jan Mattsson, Chief Operating Officer; Tom Shea, Chief Financial Officer and Treasurer; Paresh Soni, Chief Scientific Officer; and Pete Zorn, Senior Vice President, Corporate Development and General Counsel.  The board of directors of the combined organization is comprised of seven members, including five directors from Albireo Limited’s former board, David Chiswell, Ph.D., Michael Gutch, Ph.D., Heather Preston, M.D., Denise Scots-Knight, Ph.D., and Mr. Cooper, and two directors from the former Biodel board, Julia R. Brown and Davey S. Scoon.  Dr. Chiswell is the new Chairman of the Board.  The combined organization’s corporate headquarters are in Boston, Massachusetts.

About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo traces its origins to a spinout from AstraZeneca in 2008.

Albireo is located in Boston and its wholly owned direct and indirect subsidiaries are located in London and Gothenburg, Sweden. For more information on Albireo, please visit

Forward-Looking Statements
This press release includes “forward-looking statements.”  Forward-looking statements include statements, other than statements of historical fact, regarding Albireo’s intentions, plans, beliefs, expectations or forecasts for the future, including regarding our cash resources, a potentially pivotal clinical trial of A4250 in PFIC or the costs and timing for such trial.  Albireo uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements.  Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks and uncertainties, including, but not limited to: those described in the documents Biodel Inc. has filed with the Securities and Exchange Commission with regard to the share exchange transaction among Biodel, Albireo Limited and Albireo Limited shareholders and noteholders, including whether the preliminary interim data from the ongoing Phase 2 trial of A4250 in children with chronic cholestasis will be confirmed following database lock; whether the ongoing Phase 2 trial of A4250 in children with chronic cholestasis will be sufficient to support advancement into a pivotal trial in Progressive Familial Intrahepatic Cholestasis (PFIC); the timing and outcome of the planned meeting with the FDA regarding the anticipated pivotal program for A4250 in PFIC; the designs, endpoints, numbers of patients and treatment periods for trials that will be required to support approval of A4250 to treat PFIC or any other orphan pediatric liver disease; whether Albireo’s cash resources will be sufficient to advance A4250 through completion of a planned pivotal trial in PFIC; the timing for initiation or completion of, or availability of data from, ongoing or future trials of A4250, including a planned pivotal trial in PFIC; delays or other challenges in the recruitment of patients for current or future trials of any Albireo product candidate; the medical benefit that may be derived from A4250; and the competitive environment and commercial opportunity for a potential treatment for PFIC and other orphan pediatric cholestatic liver diseases.  As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law.

“Albireo” is a trademark of Albireo AB. All other trademarks, service marks, service marks, trade names, logos and brand names identified in this presentation are the properties of their respective owners.

CONTACT: Investor Contact:
Hans Vitzthum				
Managing Director			
LifeSci Advisors, LLC.		

Corporate Contact:
Ron Cooper
President and CEO
Albireo Pharma, Inc.

Ancestry Lands Science and Data Industry Veterans; Bolsters Recruiting Efforts

LEHI, Utah and SAN FRANCISCO, Nov. 03, 2016 (GLOBE NEWSWIRE) — Ancestry, the global leader in family history and consumer genomics, today announced three new appointments to its growing leadership team. As the world’s largest consumer genomics provider, having genotyped 2.5 million DNA samples, Ancestry is continuing to add to its roster of talent as it seeks to help millions of consumers better understand themselves and the world around them by unlocking the secrets hidden in their genes.

The three appointments announced today:

  • Amy Gershkoff, Ph.D., most recently the chief data officer at Zynga, is joining as Ancestry’s first chief data officer.
  • Sarah South, Ph.D., who previously served as vice president of Laboratory Operations at 23andme, has been appointed as vice president of Laboratory Sciences
  • Todd Davis, who has led global talent acquisition at both Amazon and Dropbox, is joining as vice president of Global Talent.

“Amy, Sarah and Todd are joining in three roles that will have immense impact for Ancestry as we’re focused on continuing to provide powerful insights to our community and they more than live up to the best of the best we strive for when bringing on new talent,” said Tim Sullivan, chief executive officer of Ancestry. “We are struck daily by how the insights we provide can powerfully reshape someone’s understanding of who they are and how they fit into the bigger puzzle of our species. We’re excited to have Amy, Sarah and Todd help us focus on bringing new insights, products and growth.”

Gershkoff, South and Davis bring incredible track records in their respective fields, and will help Ancestry continue to grow and innovate while providing consumers unmatched insights into their identities derived from the Company’s unique combination of genomic and genealogical data.

Amy Gershkoff was most recently the chief data officer at Zynga, a pioneer in social gaming. Previously, she built and led the Customer Analytics & Insights team and led the Global Data Science team at eBay. Before eBay, Gershkoff was the chief data scientist for WPP, Data Alliance, where she worked across WPP’s more than 350 operating companies worldwide to create integrated data and technology solutions. As the head of media planning at Obama for America for the 2012 campaign, she architected Obama’s advertising strategy and designed the campaign’s analytics systems. Her work has brought numerous accolades, including being featured in The Washington Post as one of the nation’s most prominent innovators and being named one of the “Top 50 Women to Watch in Tech” and one of San Francisco’s Most Influential Women in Business by the San Francisco Business TImes. She holds a Ph.D. from Princeton University.

Prior to joining Ancestry, Sarah South was the vice president of Laboratory Services at 23andme. She is certified in clinical cytogenetics by the American Board of Medical Genetics and Genomics (ABMGG). Previously, South was associate professor in the Department of Pathology at the University of Utah. She also served as a medical director at ARUP Laboratories and oversaw the Cytogenetic and Genomic Microarray Laboratories and directed the ABMGG clinical cytogenetics training program at the University of Utah. Sarah has also been the CLIA lab director for Lineagen. Her industry associations include, vice-chair of the American College of Medical Genetics Quality Assurance Committee; a member of the Clinical Laboratory Standards Institute Expert Panel for Molecular Methodologies and the ClinGen variant classification workgroup; a certified College of American Pathology Laboratory Inspector, and president of the American Cytogenetics Association. South also serves as an associate editor for the American Journal of Medical Genetics. She received her Ph.D. from the Johns Hopkins School of Medicine in Human Genetics, and completed a postdoctoral research fellowship in prenatal genetics at the Johns Hopkins Hospital, and a clinical cytogenetics fellowship at the University of Utah.

Todd Davis joins Ancestry from Dropbox, where he led global talent acquisition. Prior to Dropbox, Davis spent four years leading Amazon’s global efforts to find and recruit across the company. Before joining Amazon in 2012, Davis was vice president, worldwide recruitment at Warner Bros. Entertainment, where he led efforts to improve global recruitment and talent acquisition resources by leveraging “best practices” in talent assessment and selection. He has also held senior positions at Centene Corporation, West Coast University and Volt Information Sciences. Davis is a board member of CASY and MSCCN and holds a Bachelor of Science from the University of New Hampshire.

About Ancestry

Ancestry, the global leader in family history and consumer genomics, harnesses the information found in family trees, historical records, and DNA to help people gain a new level of understanding about their lives. Ancestry has more than 2.4 million paying subscribers across its core Ancestry websites and more than 2.5 million DNA samples in the AncestryDNA database. Since 1996, more than 19 billion records have been added, and users have created more than 80 million family trees on the Ancestry flagship site and its affiliated international websites. Ancestry offers a suite of family history products and services including AncestryDNA, Archives, ProGenealogists, and Fold3.

Brandon Borrman
(415) 795-6786

The Weedlife Network’s EdiblesMap, ConcentratesMap and VapePenMap Websites Provide Cannabis Consumers with One-Stop Shopping

DENVER, Nov. 03, 2016 (GLOBE NEWSWIRE) — Social Life Network, Inc. (OTC:WDLF), a business social network and digital marketplace company with media properties in the rapidly-expanding legal cannabis industry, is pleased to report strong growth in traffic numbers for The WeedLife Network’s Edibles, Concentrates and Vaporizer Pen websites. Since their debut in mid-2014, monthly traffic for the three sites has risen to over 1.6 million page views, including over 300% increase in the specific states of Colorado, Washington and California.

“Since their launch two years ago, these three websites have become an extremely valuable source for online consumers in search of dispensary locations that carry the brands and products they want and are now on pace to break two million views per month by the end of the year,” says Shawn Tapp, The WeedLife Network’s CEO and co-founder. 

The, and sites provide cannabis consumers with one-stop shopping when they search for brand-specific products at local dispensaries across the U.S. The increase in traffic is also an opportunity for The WeedLife Network to increase online advertising sales estimates to a potential $500,000 a year for the three sites.

About WeedLife ®

The WeedLife Network is a wholly-owned property of Social Life Network, Inc. which trades on OTC Markets under the symbol: WDLF. Social Life Networks, Inc. is a group of free-to-use and subscription-based social websites and marketing apps dedicated to the legal cannabis industry and specifically designed to accelerate the growth of the cannabis industry and shorten the business learning curve for new companies entering the marketplace. More information can be found at


This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company’s analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.

CONTACT: Contact: 
Bruce Kennedy

Superior Drilling Products, Inc. Announces Preliminary Third Quarter 2016 Revenue More than Double Over Trailing Quarter

  • Estimated preliminary third quarter revenue is $2.26 million
  • Sequential improvement driven by significant market penetration progress with DTI distribution agreement

VERNAL, Utah, Nov. 03, 2016 (GLOBE NEWSWIRE) — Superior Drilling Products, Inc. (NYSE MKT:SDPI) (“SDP” or the “Company”), a designer and manufacturer of drilling tool technologies, today announced its preliminary revenue estimate for the third quarter of 2016.  This estimate of revenue is subject to completion of the Company’s customary quarterly closing and the completion of the interim review procedures by the Company’s independent registered public accounting firm.

The Company estimates revenue for the third quarter of 2016 to be approximately $2.26 million, more than two times greater than $1.1 million in revenue reported for the trailing second quarter of 2016.  

Troy Meier, Chairman and CEO of SDP commented, “The sequential improvement in revenue is primarily the result of the success of our distribution agreement with Drilling Tools International (“DTI”) which has accelerated customer adoption of our Drill-N-Ream® technology.  We are seeing demand increasing from a greater number of operators.  In addition, our technology is gaining greater recognition given operators’ intense interest in identifying technologies that will enhance productivity and reduce costs as the drill rig count improves.  We have confidence in DTI’s ability and interest in achieving the market penetration goals required of them.  And, we believe that the resulting economics provides us a quicker path to achieving our goal of becoming cash flow positive early next year.  Equally as important, we remain focused on executing our growth strategy by continuously improving our technologies and inventing new innovative drill string tools.”

About Superior Drilling Products, Inc.
Superior Drilling Products, Inc. is an innovative, cutting-edge drilling tool technology company providing cost saving solutions that drive production efficiencies for the oil and natural gas drilling industry.  The Company designs, manufactures, repairs, sells and rents drilling tools.  SDP drilling solutions include the patented Drill-N-Ream® well bore conditioning tool and the patent-pending StriderTM Drill String Oscillation System.  In addition, SDP is a manufacturer and refurbisher of PDC (polycrystalline diamond compact) drill bits for a leading oil field services company.  SDP operates a state-of-the-art drill tool fabrication facility, manufacturing for its customer’s custom products and solutions for the drilling industry.  The Company’s strategy is to leverage its technological expertise in drill tool technology and innovative, precision machining to broaden its drill tool technology offerings for rent or sale, while operating an effective sales and logistics infrastructure through which it can provide proprietary tools to exploration and production companies, oilfield services companies and rental tool companies. 

Additional information about the Company can be found at its website:

Cautionary Statement Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than historical facts, that address activities (including about the Pending Acquisition) that the Company assumes, plans, expects, believes, intends or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements.  The forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. These forward-looking statements involve certain risks and uncertainties that could cause the results to differ materially from those expected by the Company’s management. Information concerning these risks and other factors can be found in the Company’s filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K, available on the Company’s website or the SEC’s website at

CONTACT: For more information, contact investor relations:
Deborah K. Pawlowski / Garett K. Gough
Kei Advisors LLC
(716) 843-3908 / (716) 846-1352 /

Native Rank, Inc. is a Finalist for the 2016 Red Herring 100 Global Award

DENVER, Nov. 03, 2016 (GLOBE NEWSWIRE) — Native Rank, Inc. today announced that it has been selected as a candidate for Red Herring’s 2016 Top 100 Global award, a prestigious recognition honoring the year’s most audacious and far-reaching private technology companies and entrepreneurs from across the globe.

The Red Herring editorial team selected the companies demonstrating the most innovative technologies and business models originating from over 1,000 companies from more than 40 nations. These companies, representing past Red Herring Asia, Europe and North America award winners in their respective regions, are judged on a range of qualitative and quantitative metrics, including but not limited to, technology innovation, financial performance, growth criterion, management’s execution standards, potential globalization of the strategy, and market share improvement.

“In today’s economies, the unrivaled technology ubiquity is not only disrupting how we work but also how we live and think. The vast amount of data and intellectual property combined with the innovation and disruption created by today’s entrepreneurs is touching every sector. More than 300 startups are striving in the construction field alone. The 2016 Red Herring nominees have proven that while some will worry about a bubble, there is no pause in innovation any time soon. And nothing must be taken for granted in this electoral year,” said Red Herring CEO, Alex Vieux. “Speed, creativity and unconventional business models are constantly shifting investors’ thesis and users’ behavior –  both are demanding more, not less, from entrepreneurs. An unprecedented number of entrepreneurs are jumping ahead of the competition and making a difference. Constant breakthroughs make recent developments obsolete faster than ever before.

In light of everything Native Rank, Inc. is performing exceptionally well in its field and deserves to be singled out as one of the Red Herring Global finalists. At this stage, we are left with the daunting task to select the best qualified companies for the 2016 Top 100 Global Award.”

The finalists are invited to present their winning strategies at the Red Herring Global forum in Los Angeles, November 15 to 17. The Top 100 winners will be announced at a special awards ceremony on November 17.

About Native Rank
Founded in 2010, Native Rank is a performance-driven digital marketing company with a history for generating great results in an array of industries across the globe. With services in both local and national SEO, PPC, web design, social media, and more, Native Rank’s ambition to be the world’s most innovative, customer-centric, and comprehensive digital marketing company is second to none, as exemplified by their recent alliance with Google as an AdWords Premier Partner. By achieving this milestone, Native Rank has proven to be an industry leader in meeting and exceeding the highest standards of client’s advertising experiences and expectations. The customer transparency and rapport they possess, the high-performance local and national campaigns they execute, and the expertise they have in more than generating traffic towards your business, but also accruing you actual customers has set the benchmark for the digital marketing industry.

About Red Herring
Red Herring is a global media company that unites the world’s best high-technology innovators, venture investors and business decision-makers in a variety of forums, including print, online and exclusive events worldwide. Red Herring provides an insider’s access to the global innovation economy, identifying new and innovative technology companies and entrepreneurs. Its Red Herring 100 awards for North America, Europe, Asia and Global have recognized more than 5,000 companies in their early stages, including Baidu, Google, eBay and Skype. For more information, please go to:

CONTACT: Contact:
Daniel Dye, EVP
(303) 524-3880

CORRECTION — Insight Celebrates Its Partners at Synergy

TEMPE, Ariz., Nov. 03, 2016 (GLOBE NEWSWIRE) — At Insight’s partner event, Synergy17 – Exploring New Horizons Together – the world’s leading technology companies came together at Sheraton Wild Horse Pass in Chandler, Ariz. for two days of presentations and discussions on strategy, marketing and growth. During the evening awards ceremony, Insight’s partners were recognized with awards celebrating our mutual successes.

Each individual award was custom designed by talented local Phoenix artist, Roy Wasson Valle, to embody this year’s theme of collaboration and the opportunities that come with it. “The award is a combination of a machine and human hand. The design brings to the forefront the connection and collaboration taking place between Insight and its partners as they explore new horizons together,” said Wasson Valle. “I am honored to once again be a part of this process.”

Last year, Wasson Valle created awards that recognized Insight’s partners in step with the company’s values of Hunger, Heart and Harmony as well as a unique piece of artwork labeled “The Heart of the Desert.” In 2013 a wildfire claimed the lives of 19 Granite Mountain Hot Shots, an elite firefighting squad in Yarnell, Ariz., leaving the community devastated by the tragedy. Valle reclaimed burned wood from amongst this destruction, giving it new purpose as the base of the Heart of the Desert Awards.

These awards were delivered to Insight’s partners to show how exploring new horizons together makes a difference for the clients whom Insight serves:

  • Synnex – Distributor Partner of the Year
  • VMware – Service Provider Partner of the Year
  • Lenovo – SMB Partner of the Year
  • HPE – Federal Partner of the Year
  • HP Inc. – Personal Hardware Growth Partner of the Year
  • Apple – Mobility Partner of the Year
  • Dell EMC – Enterprise Storage Partner of the Year
  • IBM Software– Enterprise Software Partner of the Year
  • Intel – Hardware Impact Partner of the Year
  • Adobe – Cloud Partner of the Year
  • Cisco – Software Impact Partner of the Year
  • Microsoft – Modern Workplace Partner of the Year

The following partner representatives were also recognized:

  • Megan Weir, Veritas – Software Partner Rep of the Year
  • Yana Klebanov, RSA – Software Technology Partner Rep of the Year
  • Matt Mendoza, Dell – Client Hardware Partner Rep of the Year
  • Will Banta, Plantronics – Client Hardware Technology Partner Rep of the Year
  • Ashley Taylor, HPE – Infrastructure Partner Rep of the Year
  • Susan Vail, Veeam – Infrastructure Technology Partner Rep of the Year

“Our partnerships help better serve our clients by providing them with the necessary solutions for their unique business needs and goals, now and tomorrow. Moreover, these meaningful connections are the foundation for the future of business, allowing us to seek new possibilities and opportunities together,” said Bob Kane, SVP, product marketing, Insight. “Congratulations to all of the award winners on a fantastic year, and we are excited to see what 2017 brings.”

For more information on Insight, visit or call 1.800.INSIGHT.

About Insight

From business and government organizations to healthcare and educational institutions, Insight empowers clients with Intelligent Technology™ solutions to realize their goals. As a Fortune 500-ranked global provider of hardware, software, cloud and service solutions, our 5,700 teammates provide clients the guidance and expertise needed to select, implement and manage complex technology solutions to drive business outcomes. Through our world-class people, partnerships, services and delivery solutions, we help businesses run smarter. Discover more at NSIT-M


Insight Enterprises 
TEL. (480) 333-3544

Sloane & Company
TEL. (212) 446-1884
EMAIL: AKOUVARAS@SLOANEPR.COM Announces Source Capital as Dealer-Manager for Rights Offering

SALT LAKE CITY, Nov. 03, 2016 (GLOBE NEWSWIRE) —, Inc. (NASDAQ:OSTK) announced it has contracted with Source Capital Group, Inc. to act as dealer-manager for Overstock’s previously announced rights offering.

The rights offering will allow Overstock shareholders to purchase shares of its preferred stock, including shares to be issued using the t0 (pronounced “tee-zero”) blockchain technology. The blockchain shares will trade exclusively on a registered alternative trading system using the t0 blockchain technology. Overstock is doing the rights offering primarily to enable its majority-owned subsidiary,, Inc., to demonstrate the operation of its t0 issuance and trading platform. The rights offering will allow all Overstock stockholders the opportunity to participate.

t0 is named for its ability to use blockchain technology to reduce securities trade settlement times from trade date plus three days – termed T+3 – to same-day settlement, or T+0.

“Source Capital Group is an entrepreneurial registered broker dealer that allocates time and effort toward understanding truly innovative companies,” said Source Capital’s CEO and President David Harris. “We strive to be a best of breed banker for emerging growth companies with strong identifiable cutting edge niches.

“Ever since leaving Harris Upham, which my grandfather founded, I have focused my time, and our firm’s energy on innovating and adapting to an ever-changing landscape,” Harris continued. “When Harris Upham was founded, trade and settlement was T+5, eventually changing to T+3. It only makes sense that T+0 would be the next evolutionary step. We’re excited to be a part of it.”

Overstock intends to offer up to 1 million shares of its preferred stock, and will give shareholders the opportunity to subscribe for shares of its Blockchain Voting Series A Preferred. Stockholders will also have an opportunity to subscribe for an alternative series of its preferred stock which will be economically identical to the Blockchain Voting Series A Preferred but will trade in the over-the-counter market.

Each share of the preferred stock will have voting and dividend rights and rights upon liquidation substantially similar to those of one share of common stock.  Each share of the preferred stock will also have a preferential right to a 1 percent cumulative annual cash dividend. The prospectus supplement, when filed, will contain additional important information about these and other matters.

“Source Capital Group brings not only acumen, but vision to this transaction,” said Overstock CEO Patrick M. Byrne. “The immediacy with which Source grasped the value of what we’re doing, from not only a business but from a historical point of view, made it clear that we’d found the right partner to take us through this offering.”

The expected calendar for the offering is:

Thursday, November 10, 2016 Record Date
Monday, November 14, 2016 Announcement of Maximum Price
Tuesday, November 15, 2016 Subscription Period Begins
Tuesday, December 6, 2016 Subscription Period Expires at 5:00 PM ET and Final Price is Determined

The rights offering will be made pursuant to Overstock’s effective shelf registration statement on Form S-3 (Reg. No. 333-203607) on file with the Securities and Exchange Commission (the “SEC”), and a prospectus supplement to be filed with the SEC prior to the commencement of the rights offering. The information herein is not complete and is subject to change. This press release is not an offer to sell these securities and is not soliciting an offer to buy these securities. The offering can be made only by a final prospectus, including a prospectus supplement. Investors should consider investment objectives, risks, charges and expenses carefully before investing. The base prospectus included in the registration statement contains this and additional information about Overstock, and the prospectus supplement will contain this and additional information about the rights offering, and rights holders should read both carefully before exercising their rights and investing.

Requests for copies of the base prospectus and the prospectus supplement when available, and questions from stockholders relating to the rights offering may be directed to the information agent for the rights offering, as follows:

Information Agent:
Georgeson LLC
1290 Avenue of the Americas
9th Floor
New York, NY 10104
(866) 432-2791

Source Capital Group invites any broker dealers interested in participating in the rights offering to contact Source’s syndicate department at

About, Inc. (NASDAQ:OSTK) is an online retailer based in Salt Lake City, Utah that sells a broad range of products at low prices, including furniture, rugs, bedding, electronics, clothing, and jewelry. Additional stores within Overstock include, dedicated to selling artisan-crafted products to help developing nations around the world and Main Street Revolution, supporting small-scale entrepreneurs in the U.S. by providing them with a national customer base. Other community-focused initiatives include Farmers Market and pet adoptions.  Forbes ranked Overstock in its list of the Top 100 Most Trustworthy Companies in 2014. Overstock sells internationally under the name and regularly posts information about the company and other related matters under Investor Relations on its website.

O,,,, Club O, Main Street Revolution, Worldstock and OVillage are registered trademarks of, Inc. and Space Shift are also trademarks of, Inc.  Other service marks, trademarks and trade names which may be referred to herein are the property of their respective owners.

About Source Capital Group, Inc.
Source Capital Group, Inc. was founded in 1992 as a boutique investment banking firm specializing in small to medium-sized transactions, and continues to focus its investment banking activities in those segments of the market. Source Capital has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages and business lending. Source Capital’s mission is to provide excellent service and independent, unbiased and tailor-made advice. Source Capital is registered as a broker-dealer with the SEC and in 50 states, the District of Columbia and Puerto Rico, and is a member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include all statements other than statements of historical fact. These forward-looking statements are inherently difficult to predict. Actual results, including all matters relating to the rights offering and all matters relating to our future financial results, could differ materially for a variety of reasons. Information about factors that could potentially affect our financial results is included in our Form 10-Q for the quarter ended June 30, 2016, which was filed with the SEC on August 4, 2016. These and our other subsequent filings with the SEC identify important factors that could cause our actual results to differ materially from those contained in our projections, estimates and other forward-looking statements., Inc. has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the applicable prospectus supplement for any securities offered pursuant to the registration statement, and other documents that, Inc. has filed or files in the future with the SEC for more complete information about, Inc. and the offering. You may get these documents for free by visiting EDGAR on the SEC Web site at Alternatively,, Inc. will arrange to send you the prospectus if you request it by calling 1-801-947-5409.

CONTACT: Media Contact:
Kirstie Burden,, Inc.
(801) 947-3564

Investor Contact:
Mark Harden,, Inc.
(801) 947-5409

SmartCEO Recognizes Tabula Rasa Healthcare for Its Top Corporate Culture

MOORESTOWN, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare (NASDAQ:TRHC) President Orsula V. Knowlton, PharmD, announced today the Company is being honored for its corporate culture by SmartCEO Magazine. The Award “recognizes Greater Philadelphia companies that have successfully championed a positive, productive and performance-driven culture, and have worked with their employees to develop successful cultural practices”.

“Tabula Rasa HealthCare’s Vision is to be the world’s most trusted medication risk and fiscal mitigation provider; our Credo is using our experience and talent to help others; our Mission is to enrich lives by measurably enhancing quality, improving outcomes and fostering excellence for our clients,” stated President Knowlton.

According to Jaime Nespor-Zawmon, President of SmartCEO, “The 2016 Corporate Culture Award winners have realized that running a company is more than head count and the bottom line. It’s about creating a place where creativity, energy and ideas are cultivated. Through this they are able to not only enhance performance and sustain their companies’ competitive advantages, but also enrich the lives of those they employ and inspire to make a greater impact on the world.”  

The essence of TRHC’s culture is captured in its 32 “Fundamentals” that are the foundation of its unique culture. It is called: The TRHC Way.  “We believe working on our culture is one of the most important opportunities we have to separate ourselves from the competition and become a truly world-class company,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD.

Winners will be profiled in the November/December issue of SmartCEO magazine and celebrated at an awards ceremony December 13, 2016.

About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit:

CONTACT: Contact:
Dianne Semingson
T: 215-870-0829

Bob East or Asher Dewhurst
Westwicke Partners